Wx. Zheng et al., P53 OVEREXPRESSION AND BCL-2 PERSISTENCE IN ENDOMETRIAL CARCINOMA - COMPARISON OF PAPILLARY SEROUS AND ENDOMETRIOID SUBTYPES, Gynecologic oncology, 61(2), 1996, pp. 167-174
Forty-two cases, including 21 uterine papillary serous carcinomas (UPS
C) and 21 age-, nuclear-grade-, and clinical-stage-matched uterine end
ometrioid carcinomas (UEC), were studied immunohistochemically for p53
and bcl-2 in archival paraffin-embedded tissue. Compared to UEC (28.6
% positive), UPSC (71.4% positive) had a significantly higher frequenc
y of p53 overexpression (P = 0.005); furthermore, in a clinical-stage-
matched fashion, a higher frequency of p53 overexpression was found in
early-stage cases (P = 0.032), but not in late-stage cases. In a nucl
ear-grade-matched comparison, no statistical difference in p53 overexp
ression was identified between the two subtypes, although UPSC had str
onger p53 immunoreactivity than UEC. Of UPSC, no difference in p53 ove
rexpression was detected between tumors of early and late stages; addi
tionally, in 5 cases, there was an abrupt transition from nonstaining
morphologically benign glands to uniformly positive p53 nuclear staini
ng in regions of intraepithelial carcinoma. Conversely, in UEC, there
was a significant difference in p53 immunostaining between tumors of e
arly and late stages (P = 0.01); no case had an abrupt transition for
p53 immunostaining. For bcl-2 immunostaining, UEC had a significantly
higher immunohistochemical staining score than did UPSC (P = 0.0002).
In general, the staining intensity of bcl-2 diminished progressively f
rom proliferative phase and hyperplastic endometrium to UEC and then t
o UPSC, with 3 of 21 (14.3%) UPSC being negative. These results sugges
t that p53 alteration may be an early event in the development of UPSC
and may be related to its clinical aggressiveness, while it is a late
event in UEC. Early detection of p53 nuclear accumulation may help to
identify precursor lesions of UPSC. bcl-2 persistence is frequently a
ssociated with endometrial carcinoma, and failure to inactivate bcl-2
expression probably is related to the development of endometrial carci
noma. (C) 1996 Academic Press, Inc.